Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related to the company's support of certain independent charitable co-pay foundations from 2010 to 2014 As part of these settlements, Novartis has a
Basel, June 29, 2020 - Novartis Pharma K.K. ("Novartis Pharma") today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for Japanese patients: Tabrecta(TM) (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14 skipping (METex14) mutation-posit
If approved, Xolair (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglobulin E (IgE) antibody specifically designed to target and block IgE, a key driver in the inflammatory pathway - Decision based on results from th
The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from all over the world with the aim to improve mobility, accessibility and daily life for people living with MS - Canadian company AccessNow receives t
Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made - Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide Basel, June 19, 2020 - Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible.
Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively - Lung cancer is the most common type of cancer in Japan and approximately 3,000 patients are diagnosed with METex14 metastatic NSCLC, a particularl
EMA CHMP positive opinion paves way for Cosentyx to become a first-line systemic treatment in pediatric psoriasis - CHMP opinion based on two Phase III studies showing Cosentyx provides fast and strong skin clearance and significant improvement in quality of life 1 - Moderate-to-severe psoriasis affects more than 350,000 children worldwide 2
Basel, June 25, 2020 - Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries.
83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago - 86% of tech professionals agree: the healthcare and pharma industry's "digital moment" has arrived - Report includes insights from Microsoft, MIT and Benevolent AI on the powerful pairing of science and technology to reimagine medicine.
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care - Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country - Novartis plans to roll the program out to a total of 10 African countrie
Last job offers
- Economics/Business - 3.7
Wissenschaftliche Mitarbeiterin / Wissenschaftlicher Mitarbeiter im Bereich Digital Accounting / Controlling (70-85%)
- Social Sciences - 2.7
Wissenschaftliche/r Mitarbeiter/in 100%
- Life Sciences - 2.7
Wissenschaftliche/r Mitarbeiter/in 80%
- Research Management - 2.7
Wissenschaftliche/r Mitarbeiter/in 70%
- Physics - 2.7
- Psychology - 1.7
Faculty Manager/in (deutschsprachig) in Psychologie (w/m) 40%
- Health - 30.6
Humantoxikologin / Humantoxikologe im Bereich Biozide, Toxikologie, Risikobeurteilung und Wirksamkeit
- Life Sciences - 30.6
Experienced Laboratory Manager (80-100%)